

Fernando GomollÃ³n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7217423/publications.pdf>

Version: 2024-02-01

176
papers

10,567
citations

81434

41
h-index

38517

99
g-index

212
all docs

212
docs citations

212
times ranked

9308
citing authors

#	ARTICLE	IF	CITATIONS
1	AINE, toxicidad gastrointestinal y enfermedad inflamatoria intestinal. <i>Gastroenterología Y Hepatología</i> , 2022, 45, 215-222.	0.2	19
2	Validation of screening criteria for spondyloarthritis in patients with inflammatory bowel disease in routine clinical practice. <i>Digestive and Liver Disease</i> , 2022, 54, 755-762.	0.4	1
3	Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 421.	1.0	8
4	P226 Nuclear magnetic resonance spectroscopy measure of protein glycosylation is a biomarker of activity and metabolic complications in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i275-i276.	0.6	0
5	P259 Metabolic associated Liver Disease and sex as key factors of cardiovascular risk in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i300-i301.	0.6	0
6	How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 829.	1.0	9
7	Mucosal Gene Transcript Signatures in Treatment Naïve Inflammatory Bowel Disease: A Comparative Analysis of Disease to Symptomatic and Healthy Controls in the European IBD-Character Cohort. <i>Clinical and Experimental Gastroenterology</i> , 2022, Volume 15, 5-25.	1.0	5
8	Evaluation of Natural Language Processing for the Identification of Crohn Disease-Related Variables in Spanish Electronic Health Records: A Validation Study for the PREMONITION-CD Project. <i>JMIR Medical Informatics</i> , 2022, 10, e30345.	1.3	8
9	Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1255-1268.	0.6	17
10	Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease Severity. <i>Biomedicines</i> , 2022, 10, 727.	1.4	4
11	Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 699-708.	0.6	36
12	La enfermedad inflamatoria intestinal y los riesgos de enfermedad cardiovascular. <i>Gastroenterología Y Hepatología</i> , 2021, 44, 236-242.	0.2	5
13	Inflammatory bowel disease and the risk of cardiovascular diseases. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2021, 44, 236-242.	0.0	3
14	Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment. <i>Nutrients</i> , 2021, 13, 1770.	1.7	6
15	Are Steroids Still Useful in Immunosuppressed Patients With Inflammatory Bowel Disease? A Retrospective, Population-Based Study. <i>Frontiers in Medicine</i> , 2021, 8, 651685.	1.2	4
16	Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2885.	1.0	38
17	Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?. <i>Frontiers in Medicine</i> , 2021, 8, 681907.	1.2	12
18	Small and Large Intestine (II): Inflammatory Bowel Disease, Short Bowel Syndrome, and Malignant Tumors of the Digestive Tract. <i>Nutrients</i> , 2021, 13, 2325.	1.7	12

#	ARTICLE	IF	CITATIONS
19	Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study). <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1041-1051.	1.9	6
20	Inflammatory bowel disease and corticosteroids: the first RCT. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 833-833.	8.2	2
21	Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112239.	2.5	9
22	Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry. <i>Journal of Crohn's and Colitis</i> , 2021, . .	0.6	6
23	A Patient Self-Made Point-of-Care Fecal Test Improves Diagnostic Accuracy Compared with Fecal Calprotectin Alone in Inflammatory Bowel Disease Patients. <i>Diagnostics</i> , 2021, 11, 2323.	1.3	1
24	Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 606-616.	0.9	29
25	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 4-22.	0.6	741
26	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 155-168.	0.6	478
27	Año 1977: el componente activo de la sulfasalazina es el ácido 5-aminosalicílico. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 369-370.	0.2	0
28	Año 1994: resistencia y dependencia de los esteroides en pacientes con Crohn. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 377-378.	0.2	0
29	Año 1955: primer ensayo clínico en enfermedad inflamatoria: los corticoides reducen la mortalidad. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 367-368.	0.2	0
30	Año 1990: predicción del curso de la enfermedad de Crohn después de la cirugía. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 375-376.	0.2	0
31	Año 2001: asociación entre la susceptibilidad a la enfermedad de Crohn y las variaciones de LRR. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 381-382.	0.2	0
32	Año 1979: resultados del tratamiento farmacológico de la enfermedad de Crohn. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 371-372.	0.2	0
33	P544 Comparison of the efficacy of a second intravenous or subcutaneous anti-TNF in the treatment of ulcerative colitis: Real-world data from the ENEIDA registry. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S463-S464.	0.6	0
34	El registro ENEIDA (Estudio Nacional en Enfermedad Inflamatoria intestinal sobre Determinantes) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1</i> <i>Hepatología</i> , 2020, 43, 551-558.	0.2	33
35	Año 1932: descripción inicial detallada de la enteritis regional. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 363-364.	0.2	0
36	Año 2005: clasificación clínica, serológica y molecular de la enfermedad inflamatoria intestinal. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 383-384.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Año 1938: primer reconocimiento de la enfermedad perianal como parte de la enfermedad de Crohn. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 365-366.	0.2	0
38	Año 1997: estudio a corto plazo del anticuerpo monoclonal quimérico cA2 contra el factor de necrosis tumoral alfa para la enfermedad de Crohn. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 379-380.	0.2	0
39	Año 1983: el tabaquismo disminuye el riesgo de colitis ulcerosa. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 373-374.	0.2	0
40	Mo1618 THE USE OF A QUICK AND EASY FAECAL TEST AS A TOOL TO AVOID NON-PATHOLOGICAL COLONOSCOPIES AND PRIORITIZE HIGH RISK SYMPTOMATIC PATIENTS. <i>Gastroenterology</i> , 2020, 158, S-918.	0.6	0
41	Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character). <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1146-1156.	0.6	20
42	Su1912 CDEIS SCORE OF 2 IS OPTIMAL CUT-OFF ASSOCIATED WITH LOWER RISK OF DISEASE PROGRESSION IN EARLY CROHN'S DISEASE: DATA FROM THE CALM STUDY. <i>Gastroenterology</i> , 2020, 158, S-699.	0.6	0
43	Year 1938: First recognition of the perianal disease as part of Crohn's disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020, 43, 365-366.	0.0	0
44	Year 1932: The first detailed description of regional enteritis. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020, 43, 363-364.	0.0	0
45	Year 1977: The active component of sulphasalazine is 5-aminosalicylic acid. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020, 43, 369-370.	0.0	0
46	Year 1979: Results from the pharmacological treatment of Crohn's disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020, 43, 371-372.	0.0	0
47	Year 1983: Smoking decreases the risk of ulcerative colitis. <i>Gastroenterología Y Hepatología (English)</i> Tj ETQq1 1 0,784314,rgBT /O	0.0	0
48	Year 1990: Predictability of the postoperative course of Crohn's disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020, 43, 375-376.	0.0	0
49	Year 1994: Corticosteroid resistance and dependence among patients with Crohn's disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020, 43, 377-378.	0.0	0
50	Year 1997: Short-term study of the cA2 chimeric monoclonal antibody directed against human tumour necrosis factor-alpha for Crohn's disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020, 43, 379-380.	0.0	0
51	Year 2001: Link between susceptibility to Crohn's disease and variations in LRR. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020, 43, 381-382.	0.0	0
52	Year 2005: Clinical, serological and molecular classification of inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020, 43, 383-384.	0.0	0
53	Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2080-2087.	1.4	11
54	Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 588-596.	0.8	6

#	ARTICLE	IF	CITATIONS
55	Mo1115 WHOLE-BLOOD EXPRESSION PROFILES IN INFLAMMATORY BOWEL DISEASE REVEAL TRANSCRIPTION FACTOR INVOLVEMENT. <i>Gastroenterology</i> , 2020, 158, S-792-S-793.	0.6	0
56	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. <i>Gastroenterology</i> , 2020, 159, 139-147.	0.6	126
57	Whole Blood Profiling of T-cell-Derived microRNA Allows the Development of Prognostic models in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1724-1733.	0.6	16
58	Recommendations by the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of patients with inflammatory bowel disease associated with spondyloarthritis. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020, 43, 273-283.	0.0	3
59	Mo1860 REAL-WORLD LONG-TERM EFFECTIVENESS OF USTEKINUMAB IN CROHN'S DISEASE: RESULTS FROM THE ENEIDA REGISTRY. <i>Gastroenterology</i> , 2020, 158, S-953.	0.6	1
60	P744 Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): Results from the nationwide Epidemiology study of GETECCU. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S594-S597.	0.6	7
61	Idiopathic acute pancreatitis in patients with inflammatory bowel disease: A multicenter cohort study. <i>Pancreatology</i> , 2020, 20, 331-337.	0.5	11
62	P240 CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohn's disease: Data from the CALM study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S264-S266.	0.6	0
63	P386 Long-term evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (IBD): A multicentre study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S359-S360.	0.6	0
64	P774 Low adherence to latent tuberculosis (TB) screening recommendations in inflammatory bowel disease (IBD) patients: Results of the INFELL registry of GETECCU. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S614-S615.	0.6	0
65	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. <i>Drugs</i> , 2020, 80, 99-113.	4.9	58
66	Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1290-1298.	0.6	5
67	Guía GETECCU 2020 para el tratamiento de la colitis ulcerosa. Elaborada con metodología GRADE. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 1-57.	0.2	24
68	The combination of quantitative faecal occult blood test and faecal calprotectin is a cost-effective strategy to avoid colonoscopies in symptomatic patients without relevant pathology. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092078.	1.4	14
69	Tratamiento inicial y del fracaso en la erradicación de la infección por <i>Helicobacter pylori</i> . <i>Medicine</i> , 2020, 13, 106-110.	0.0	0
70	Historia de la enfermedad inflamatoria intestinal en once infografías. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 362.	0.2	0
71	The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory) <i>Tj ETQq1 1 0.784314 rgBT /Overdo</i> (English Edition), 2020, 43, 551-558.	0.0	7
72	Is there any alternative to science? Complementary and alternative therapies for inflammatory bowel diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 664-666.	3.7	1

#	ARTICLE	IF	CITATIONS
73	Tu2036 " A Patient Self-Made One Step Quick Faecal Test Reduces Unnecessary Colonoscopies and Prioritizes High Risk Symptomatic Patients. <i>Gastroenterology</i> , 2019, 156, S-1176-S-1177.	0.6	0
74	Increased risk of thiopurine-related adverse events in elderly patients with IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 780-788.	1.9	40
75	Sa1812 " Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm. <i>Gastroenterology</i> , 2019, 156, S-411.	0.6	5
76	Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986784.	1.4	1
77	OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn's disease: long-term data from CALM. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S024-S025.	0.6	12
78	Primary sclerosing cholangitis and inflammatory bowel disease: Intestine-liver interrelation. <i>Gastroenterology Y Hepatología (English Edition)</i> , 2019, 42, 316-325.	0.0	6
79	EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481984703.	1.4	18
80	Mo1636 " The Addition of Other Faecal Biomarkers to Immunological Faecal Occult Blood Test is Not Effective to Avoid Normal Colonoscopies in a Colorectal Cancer Screening Program. <i>Gastroenterology</i> , 2019, 156, S-811.	0.6	0
81	Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1862-1870.	0.9	28
82	Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease. <i>Pharmacogenomics Journal</i> , 2019, 19, 547-555.	0.9	4
83	Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease – associations with disease phenotype, treatment, and outcome. <i>Clinical and Experimental Gastroenterology</i> , 2019, Volume 12, 37-49.	1.0	58
84	Young age and tobacco use are predictors of lower medication adherence in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 948-953.	0.8	12
85	Bioequivalence studies with anti-TNF biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1031-1043.	1.4	8
86	Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2019, 64, 846-854.	1.1	24
87	Accuracy of the Narrow-Band Imaging International Colorectal Endoscopic Classification System in Identification of Deep Invasion in Colorectal Polyps. <i>Gastroenterology</i> , 2019, 156, 75-87.	0.6	75
88	Colangitis esclerosante primaria y enfermedad inflamatoria intestinal: interrelaci3n intestino-h3gado. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 316-325.	0.2	14
89	Post-Operative Morbidity and Mortality of a Cohort of Steroid Refractory Acute Severe Ulcerative Colitis: Nationwide Multicenter Study of the GETECCU ENEIDA Registry. <i>American Journal of Gastroenterology</i> , 2018, 113, 1009-1016.	0.2	30
90	P391 The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn's disease but not in ulcerative colitis. A nationwide study from the Eneida registry. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S301-S302.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Screening of Inflammatory Bowel Disease and Spondyloarthritis for Referring Patients Between Rheumatology and Gastroenterology. <i>Reumatología Clínica (English Edition)</i> , 2018, 14, 68-74.	0.2	6
92	Screening of inflammatory bowel disease and spondyloarthritis for referring patients between rheumatology and gastroenterology. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018, 41, 54-62.	0.0	0
93	Criterios de cribado de enfermedad inflamatoria intestinal y espondiloartritis para derivación de pacientes entre Reumatología y Gastroenterología. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 54-62.	0.2	10
94	Criterios de cribado de enfermedad inflamatoria intestinal y espondiloartritis para derivación de pacientes entre Reumatología y Gastroenterología. <i>Reumatología Clínica</i> , 2018, 14, 68-74.	0.2	13
95	OWE-008...Patients'™ perception of faecal calprotectin testing in inflammatory bowel disease: a multi-centre prospective survey. , 2018, , .		0
96	P524 Active smoking and personal concerns about treatment can impair adherence to adalimumab in inflammatory bowel diseases: A prospective evaluation. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S371-S371.	0.6	1
97	Validation of a self-reported work disability questionnaire for ulcerative colitis. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlock</i>	0.4	1
98	Patients'™ perceptions of faecal calprotectin testing in inflammatory bowel disease: results from a prospective multicentre patient-based survey*. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1437-1442.	0.6	19
99	Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm. <i>Nutrients</i> , 2018, 10, 1959.	1.7	19
100	Su1004 - Combination of Quantitative Faecal Occult Blood Test and Fecal Calprotectin is a Cost-Effective Strategy to Avoid Non Pathological Colonoscopies in Symptomatic Patients. <i>Gastroenterology</i> , 2018, 154, S-450-S-451.	0.6	0
101	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el tratamiento de pacientes con espondiloartritis asociada a enfermedad inflamatoria intestinal. <i>Enfermedad Inflamatoria Intestinal Al Día</i> , 2017, 16, 1-14.	0.2	0
102	Sonda nasogástrica: un tormento innecesario. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 58.	0.2	0
103	Cost-utility of biological treatment sequences for luminal Crohn's™ disease in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 597-606.	0.7	22
104	Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. <i>American Journal of Gastroenterology</i> , 2017, 112, 1135-1143.	0.2	27
105	Nasogastric intubation: Needless torture. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2017, 40, 58.	0.0	0
106	Epigenetic alterations in inflammatory bowel disease: the complex interplay between genome-wide methylation alterations, germline variation, and gene expression. <i>Lancet, The</i> , 2017, 389, S52.	6.3	2
107	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 120-131.	0.2	93
108	Surgery in ileocaecal Crohn's disease: one more option, sometimes the best?. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 768-769.	3.7	4

#	ARTICLE	IF	CITATIONS
109	Inflammatory Bowel Disease and Eating Disorders: A systematized review of comorbidity. <i>Journal of Psychosomatic Research</i> , 2017, 102, 47-53.	1.2	63
110	Epigenetic Alterations at Diagnosis Predict Susceptibility, Prognosis and Treatment Escalation in Inflammatory Bowel Disease and IBD Character. <i>Gastroenterology</i> , 2017, 152, S565.	0.6	1
111	Proximity Extension Assay based Proteins Show Immune Cell Specificity and can Diagnose and Predict Outcomes in Inflammatory Bowel Diseases: IBD Character Study. <i>Gastroenterology</i> , 2017, 152, S606-S607.	0.6	2
112	Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 1709-1718.	0.2	55
113	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 3-25.	0.6	1,547
114	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 135-149.	0.6	558
115	Oral Cyanocobalamin is Effective in the Treatment of Vitamin B12 Deficiency in Crohn's Disease. <i>Nutrients</i> , 2017, 9, 308.	1.7	15
116	P788 Microbiota related disease activity and distribution in subgroups of inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S483-S484.	0.6	0
117	Genetic variation associated with cardiovascular risk in autoimmune diseases. <i>PLoS ONE</i> , 2017, 12, e0185889.	1.1	5
118	Current misconceptions in diagnosis and management of iron deficiency. <i>Blood Transfusion</i> , 2017, 15, 422-437.	0.3	83
119	Biosimilars in inflammatory bowel disease. <i>Minerva Medica</i> , 2017, 108, 239-254.	0.3	8
120	Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 583-598.	0.9	2
121	IV Spanish Consensus Conference on Helicobacter pylori infection treatment. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2016, 39, 697-721.	0.0	27
122	Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab. <i>Biochemical Pharmacology</i> , 2016, 122, 33-41.	2.0	12
123	La adherencia al tratamiento es siempre peor de lo que cada uno pensamos. Un problema a resolver en la enfermedad inflamatoria intestinal. <i>Gastroenterología Y Hepatología</i> , 2016, 39, 14-19.	0.2	2
124	IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. <i>Gastroenterología Y Hepatología</i> , 2016, 39, 697-721.	0.2	97
125	Response to To et al.. <i>American Journal of Gastroenterology</i> , 2016, 111, 1198-1199.	0.2	0
126	Cost-effectiveness assessment through theoretical cost-minimization analysis of the use of two gastro-resistant modified-release mesalazine formulations in the management of ulcerative colitis in Spain. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2016, 39, 199-212.	0.0	1

#	ARTICLE	IF	CITATIONS
127	Impact of Smoking Cessation on the Clinical Course of Crohn's Disease Under Current Therapeutic Algorithms: A Multicenter Prospective Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 411-419.	0.2	58
128	Intestinal Serotonin Transporter Inhibition by Toll-Like Receptor 2 Activation. A Feedback Modulation. <i>PLoS ONE</i> , 2016, 11, e0169303.	1.1	29
129	High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life. <i>Blood Transfusion</i> , 2016, 14, 199-205.	0.3	19
130	Biosimilars in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 290-295.	1.0	22
131	IBD-related work disability in the community: Prevalence, severity and predictive factors. A cross-sectional study. <i>United European Gastroenterology Journal</i> , 2015, 3, 335-342.	1.6	37
132	Identification of Risk Loci for Crohn's Disease Phenotypes Using a Genome-Wide Association Study. <i>Gastroenterology</i> , 2015, 148, 794-805.	0.6	46
133	European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 211-222.	0.6	425
134	Delphi consensus statement: Quality indicators for Inflammatory Bowel Disease Comprehensive Care Units. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 240-251.	0.6	89
135	Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1287-1293.	0.6	24
136	A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis. <i>Human Molecular Genetics</i> , 2014, 23, 6927-6934.	1.4	39
137	Does Smoking Influence Crohn's Disease in the Biologic Era? The TABACROHN Study. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 23-29.	0.9	42
138	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 1-33.	0.6	422
139	Current Management of Iron Deficiency Anemia in Inflammatory Bowel Diseases: A Practical Guide. <i>Drugs</i> , 2013, 73, 1761-1770.	4.9	35
140	The GETECCU clinical guideline for the treatment of ulcerative colitis: A guideline created using GRADE methodology. <i>Gastroenterology & Hepatology</i> , 2013, 36, 483.e1-483.e46.	0.2	2
141	Therapeutic guidelines on ulcerative colitis: A GRADE methodology based effort of GETECCU. <i>Gastroenterology & Hepatology</i> , 2013, 36, 104-114.	0.2	44
142	High smoking cessation rate in Crohn's disease patients after physician advice " The TABACROHN Study. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 202-207.	0.6	43
143	ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). <i>Journal of Crohn's and Colitis</i> , 2013, 7, 586-589.	0.6	169
144	A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at <i>10q26</i> . <i>Gut</i> , 2013, 62, 1440-1445.	6.1	42

#	ARTICLE	IF	CITATIONS
145	Intravenous iron in inflammatory bowel diseases. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 201-207.	1.0	23
146	Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 752-760.	1.9	73
147	Safety of Thiopurine Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1404-1410.	0.9	243
148	Intravenous iron in digestive diseases. <i>Transfusion Alternatives in Transfusion Medicine</i> , 2012, 12, 122-129.	0.2	2
149	What changes in inflammatory bowel disease management can be implemented today?. <i>Journal of Crohn's and Colitis</i> , 2012, 6, S260-S267.	0.6	5
150	Adherence of gastroenterologists to European Crohn's and Colitis Organisation Consensus on Crohn's disease: A real-life survey in Spain. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 763-770.	0.6	13
151	Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 275-283.	1.9	102
152	Early Use of Azathioprine Has a Steroid Sparing Effect on Recently Diagnosed Crohn's Disease Patients. <i>Gastroenterology</i> , 2011, 140, S-109.	0.6	16
153	Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose Escalation in Patients Losing Response. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 113-118.	1.1	114
154	Intravenous iron in digestive diseases: a clinical (re)view. <i>Therapeutic Advances in Chronic Disease</i> , 2010, 1, 67-75.	1.1	11
155	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 28-62.	0.6	1,247
156	Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: A real-life survey in Spain. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 567-574.	0.6	29
157	Carta respuesta. <i>Gastroenterología Y Hepatología</i> , 2010, 33, 472-473.	0.2	0
158	Anemia and inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2009, 15, 4659.	1.4	162
159	Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1746-1754.	0.9	97
160	Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 126-137.	1.9	186
161	P119 - Efficacy of azathioprine and mercaptopurine in ulcerative colitis. Systematic review and meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2009, 3, S58.	0.6	0
162	Anemia and digestive diseases: An update for the clinician. <i>World Journal of Gastroenterology</i> , 2009, 15, 4615.	1.4	13

#	ARTICLE	IF	CITATIONS
163	Blood transfusion for the treatment of acute anaemia in inflammatory bowel disease and other digestive diseases. <i>World Journal of Gastroenterology</i> , 2009, 15, 4686.	1.4	35
164	Common Misconceptions in the Diagnosis and Management of Anemia in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 1299-1307.	0.2	191
165	Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review. <i>American Journal of Gastroenterology</i> , 2008, 103, 1783-1800.	0.2	223
166	Are we giving azathioprine too much time?. <i>World Journal of Gastroenterology</i> , 2008, 14, 5519.	1.4	7
167	Crohnology: A tale of time and times and inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2008, 14, 5489.	1.4	0
168	Crohn's Disease. <i>Drugs</i> , 2007, 67, 2511-2537.	4.9	60
169	Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases#. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1545-1553.	0.9	373
170	Optimising Acid Inhibition Treatment. <i>Drugs</i> , 2005, 65, 25???33.	4.9	4
171	Low Frequency of Upper Gastrointestinal Complications in a Cohort of High-Risk Patients Taking Low-Dose Aspirin or NSAIDs and Omeprazole. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 693-700.	0.6	45
172	Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. <i>Digestive Diseases and Sciences</i> , 2002, 47, 471-488.	1.1	97
173	<i>Helicobacter pylori</i> : strategies for treatment. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 1231-1241.	1.9	4
174	Third line treatment for <i>Helicobacter pylori</i> : a prospective, culture-guided study in peptic ulcer patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 1335-1338.	1.9	69
175	Impact of clarithromycin resistance on the effectiveness of a regimen for <i>Helicobacter pylori</i> : a prospective study of 1-week lansoprazole, amoxicillin and clarithromycin in active peptic ulcer. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 775-780.	1.9	90
176	Quadruple Therapy Is Effective for Eradicating <i>Helicobacter pylori</i> After Failure of Triple Proton-Pump Inhibitor-Based Therapy: A Detailed, Prospective Analysis of 21 Consecutive Cases. <i>Helicobacter</i> , 1999, 4, 222-225.	1.6	68